Starling Oncology (STLNW) Acquisitions (2021 - 2023)

Starling Oncology (STLNW) has reported Acquisitions for 3 consecutive years, with $156000.0 the latest figure, recorded in Q4 2023.

• For the quarter ending Q4 2023, Acquisitions fell 66.81% year-over-year to $156000.0; the trailing twelve-month figure through Dec 2024 stood at $156000.0 (up 183.42% YoY), and the FY2023 full-year result was $4.5 million, down 48.05% from the prior year.
• Acquisitions eased to $156000.0 in Q4 2023 per STLNW's latest filing, from $470000.0 in the prior quarter.
• Across five years, Acquisitions topped out at $8.9 million in Q2 2022 and bottomed at -$813000.0 in Q3 2022.
• Historically, Acquisitions has averaged $3.0 million across 3 years, with a median of $648500.0 in 2021.
• The sharpest annual moves came in 2022 and 2023: Acquisitions plunged 94.32% in 2022, then slumped 66.81% in 2023.
• Over 3 years, Acquisitions stood at $8.3 million in 2021, then slumped by 94.32% to $470000.0 in 2022, then plunged by 66.81% to $156000.0 in 2023.
• According to Business Quant data, Acquisitions over the past three periods registered $156000.0, $470000.0, and -$813000.0 for Q4 2023, Q4 2022, and Q3 2022 respectively.